ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - catype/medical-oncology/breast/metastatic/her2-positive
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
Breast / Breast - Metastatic / HER2-positive
12
trial(s) found.
NCT07465172
Advanced
NA
Not yet recruiting
A Multi-centre, Prospective Cohort Study to Explore the Relationship Between Changes in GDF-15 Levels and Treatment-related Adverse Events During T-DXd Treatment in Breast Cancer Patients. (
GRADE
)
anti-ERBB2 antibody-drug conjugate
Breast cancer
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT06966453
Advanced
Phase 1 / Phase 2
Recruiting
A PHASE 1b/2, OPEN-LABEL, MULTICOHORT STUDY OF DISITAMAB VEDOTIN IN ADULTS WITH HER2 EXPRESSING ADVANCED BREAST CANCER (
C5731006
)
anti-ERBB2 antibody-drug conjugate
Breast cancer
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
VIC
3021 - St Albans - Western Health - Sunshine Hospital
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
NCT06760819
Advanced
Phase 2
Recruiting
A Phase 2 Open-label Basket Study to Evaluate the Efficacy and Safety of Orally Administered Reversible Tyrosine Kinase Inhibitor BAY 2927088 in Participants With Metastatic or Unresectable Solid Tumors With HER2-activating Mutations (
panSOHO
)
EGFR/ERBB2 inhibitor,mutant-selective,non-covalent
Breast cancer
Cervical cancer
Colorectal adenocarcinoma
Endometrial cancer
NOT Biliary tract cancer
NOT Colorectal cancer
NOT Non-small cell lung cancer
NOT Urothelial carcinoma
Urothelial carcinoma
NSW
2109 - North Ryde - Macquarie University Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
QLD
4215 - Southport - ICON Cancer Care
NCT06625775
Advanced
Phase 1
Recruiting
A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-10203 in Subjects With Advanced Solid Tumors (The BREAKER-101 Study) (
TBBO10203-101
)
PI3K alpha-RAS breaker
Breast cancer
Colorectal cancer
HER2-negative breast cancer
HER2-positive breast cancer
Non-small cell lung cancer
RAS-mutant colorectal cancer
NSW
2031 - Randwick - Scientia Clinical Research Ltd
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT06581432
Advanced
Phase 2
Recruiting
Beamion PANTUMOR-1: A Phase II, Multicentre, Multicohort, Open-label Trial to Evaluate the Efficacy and Safety of Oral Zongertinib (BI 1810631) for the Treatment of Selected HER2-mutated or Overexpressed/Amplified Solid Tumours (
1479-0009
)
ERBB2 inhibitor,second generation
Cervical cancer
Gastroesophageal junction adenocarcinoma
NOT Breast cancer
NOT Colorectal adenocarcinoma
NOT Gastroesophageal cancer
NOT Pancreatic adenocarcinoma
NOT Pancreatic cancer
NOT Squamous non-small-cell lung cancer
Non-small cell lung cancer
Solid tumour
Urothelial carcinoma
NSW
2065 - St Leonards - GenesisCare North Shore Private Hospital
2109 - North Ryde - Macquarie University Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
NCT06435429
Advanced
Phase 3
Recruiting
A Phase 3, Randomized, Open-label, Multicenter, Controlled Study to Evaluate the Efficacy and Safety of Zanidatamab in Combination With Physician's Choice Chemotherapy Compared to Trastuzumab in Combination With Physician's Choice Chemotherapy for the Treatment of Participants With Metastatic HER2-positive Breast Cancer Who Have Progressed on, or Are Intolerant to, Previous Trastuzumab Deruxtecan Treatment (
JZP598-303
)
anti-ERBB2 antibody-drug conjugate
anti-ERBB2 monoclonal antibody
bispecific ERBB2/ERBB2 antibody
HER2-positive breast cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
3149 - Mount Waverley - Waverley Private Hospital - Oncology
QLD
4575 - Sunshine Coast - Sunshine Coast University Private Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
NCT06157892
Advanced
Phase 2
Recruiting
A Phase 1b/2 Open-Label Study of Disitamab Vedotin in Combination With Other Anticancer Therapies in Solid Tumors (
SGNDV-004
)
anti-ERBB2 antibody-drug conjugate
Breast cancer
Gastric cancer
Gastroesophageal junction adenocarcinoma
HER2-low breast cancer
HER2-positive breast cancer
Triple-negative breast cancer
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3199 - Frankston - Peninsula Health Frankston Hospital
NA
NA
NCT05950945
Advanced
Phase 3
Recruiting
A Phase 3b, Multicenter, Global, Interventional, Open-label Study of Trastuzumab Deruxtecan (T-DXd), an Anti-HER2-Antibody Drug Conjugate (ADC), in Subjects Who Have Unresectable and/or Metastatic HER2-low or HER2 Immunohistochemistry (IHC) 0 Breast Cancer (DESTINY-Breast15) (
DS8201-0001-CIS-MA
)
anti-ERBB2 antibody-drug conjugate
Breast cancer
NSW
2060 - North Sydney - Mater Hospital (TERMINATED)
VIC
3165 - East Bentleigh - Peter MacCallum Cancer Centre Moorabbin Campus (TERMINATED)
SA
5000 - South Australia - GenesisCare St Andrews Hospital (TERMINATED)
WA
6150 - Murdoch - Fiona Stanley Hospital (WITHDRAWN)
NCT05872295
Advanced
Phase 1
Recruiting
A Phase 1 Dose Escalation Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of IKS014, a HER2-Targeting Antibody Drug Conjugate (ADC), in Participants With Advanced HER2+ Solid Tumors (
IKS014-01
)
anti-ERBB2 antibody-drug conjugate
Breast cancer
Gastric cancer
Gastroesophageal junction adenocarcinoma
Solid tumour
NSW
2109 - North Ryde - Macquarie University Hospital
2139 - Concord - Concord Repatriation General Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
3199 - Frankston - Peninsula Health Frankston Hospital
WA
6009 - Nedlands - Linear Clinical Research
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT04802759
Advanced
Phase 1 / Phase 2
Recruiting
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Breast Cancer (MORPHEUS-BREAST CANCER) (
CO42867
)
AKT inhibitor
Abemaciclib
Atezolizumab
CDK4/6 inhibitor
CDK4 inhibitor
CDK6 inhibitor
CDK7 inhibitor
ER degrader
Everolimus
Giredestrant
Inavolisib
Ipatasertib
PI3K alpha inhibitor
Palbociclib
Pertuzumab
Ribociclib
Samuraciclib
anti-ERBB2 monoclonal antibody
anti-ERBB2 monoclonal antibody,dimerization inhibitor
anti-PD-L1 monoclonal antibody
cancer therapy
cancer therapy,AKT-targeting
cancer therapy,CDK4-targeting
cancer therapy,CDK6-targeting
cancer therapy,CDK7-targeting
cancer therapy,ERBB2-targeting
cancer therapy,ESR1-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PD-L1-targeting
cancer therapy,PI3Kalpha-targeting
cancer therapy,mTOR-targeting
cancer therapy,mTORC1-targeting
endocrine therapy
endocrine therapy,oestrogen axis-targeting
immune checkpoint blockade
immune checkpoint blockade,PD-L1-targeting
immuno-oncology therapy,ERBB2-targeting
immuno-oncology therapy,PD-L1-targeting
mTORC1 inhibitor
mTOR inhibitor
oestrogen receptor-targeting therapy
pan-AKT inhibitor
selective estrogen receptor degrader
Breast cancer
ER-positive breast cancer
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3199 - Frankston - Peninsula Health Frankston Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Linear Clinical Research
NCT03424005
Advanced
Phase 1 / Phase 2
Recruiting
A Phase Ib/II, Open-label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic Breast Cancer (
Morpheus-panBC
)
AKT inhibitor
Abemaciclib
Atezolizumab
Atirmociclib
Bevacizumab
CDK4/6 inhibitor
CDK4 inhibitor
CDK4 selective inhibitor
CDK6 inhibitor
Capecitabine
Carboplatin
ER degrader
Eribulin
Fulvestrant
Gemcitabine
Inavolisib
Ipatasertib
Ladiratuzumab Vedotin
Letrozole
Metformin
Nab-paclitaxel
PI3K alpha inhibitor
Palbociclib
Ribociclib
Sacituzumab Govitecan
Selicrelumab
Tocilizumab
Trastuzumab Deruxtecan
agnostic antibody,CD40-targeting
anti-CD40 agonistic antibody
anti-ERBB2 antibody-drug conjugate
anti-IL-6 monoclonal antibody
anti-LIV1 antibody-drug conjugate
anti-PD-L1 monoclonal antibody
anti-Trop2 antibody-drug conjugate
anti-VEGF monoclonal antibody
antimetabolite
aromatase inhibitor
biguanide antihyperglycaemic agent
cancer therapy
cancer therapy,AKT-targeting
cancer therapy,CD40-targeting
cancer therapy,CDK4-targeting
cancer therapy,CDK4 selective-targeting
cancer therapy,CDK6-targeting
cancer therapy,ERBB2-targeting
cancer therapy,ESR1-targeting
cancer therapy,IL-6-targeting
cancer therapy,LIV1-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PD-L1-targeting
cancer therapy,PI3Kalpha-targeting
cancer therapy,Trop2-targeting
cancer therapy,VEGF-targeting
cytotoxic chemotherapy
endocrine therapy
endocrine therapy,oestrogen axis-targeting
fluoropyrimidine
immune checkpoint blockade
immune checkpoint blockade,PD-L1-targeting
immuno-oncology therapy,CD40-targeting
immuno-oncology therapy,ERBB2-targeting
immuno-oncology therapy,IL-6-targeting
immuno-oncology therapy,LIV1-targeting
immuno-oncology therapy,PD-L1-targeting
immuno-oncology therapy,Trop2-targeting
immuno-oncology therapy,VEGF-targeting
macrocyclic ketone analogue
oestrogen receptor-targeting therapy
pan-AKT inhibitor
platinum-based antineoplastic agent
selective estrogen receptor degrader
taxane
Breast cancer
VIC
3002 - Melbourne - Peter MacCallum Cancer Centre, East Melbourne campus
WA
6150 - Murdoch - Fiona Stanley Hospital
ACTRN12622000016730
Advanced
Phase 1
Recruiting
Addition of prochlorperazine to paclitaxel, trastuzumab, and pertuzumab for previously untreated HER2-positive metastatic breast cancer: a phase 1 dose de-escalation study (
HER2Pro-1B
)
anti-ERBB2 monoclonal antibody
anti-ERBB2 monoclonal antibody,dimerization inhibitor
antihistamine
taxane
HER2-positive breast cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (11)
Not yet recruiting (1)
Recruitment Country and State
VIC (8)
NSW (7)
QLD (5)
WA (5)
SA (3)
NZ (1)
Phase
Phase 1 (3)
Phase 1 / Phase 2 (3)
Phase 2 (3)
Phase 3 (2)
Trial Type
Advanced (12)
Cancer Therapy Class
ERBB2
100%
CDK4
25%
CDK6
25%
ER
25%
PI3Kalpha
25%
oestrogen axis
25%
VEGF
17%
AKT
17%
PD-1/PD-L1
17%
PD-L1
17%
EGFR
8%
CDK7
8%
mTOR
8%
mTORC1
8%
CD40
8%
CDK4 selective
8%
IL-6
8%
LIV1
8%
Trop2
8%
Facility
3000 - Melbourne - Peter MacCallum Cancer Centre (4)
2109 - North Ryde - Macquarie University Hospital (3)
3199 - Frankston - Peninsula Health Frankston Hospital (3)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (2)
4102 - Woolloongabba - Princess Alexandra Hospital (2)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (2)
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (2)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (2)
6150 - Murdoch - Fiona Stanley Hospital (2)
6009 - Nedlands - Linear Clinical Research (2)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (1)
3021 - St Albans - Western Health - Sunshine Hospital (1)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (1)
4215 - Southport - ICON Cancer Care (1)
2031 - Randwick - Scientia Clinical Research Ltd (1)
2065 - St Leonards - GenesisCare North Shore Private Hospital (1)
3128 - Box Hill - Box Hill Hospital - Eastern Health (1)
3149 - Mount Waverley - Waverley Private Hospital - Oncology (1)
4575 - Sunshine Coast - Sunshine Coast University Private Hospital (1)
NA
2060 - North Sydney - Mater Hospital (1)
3165 - East Bentleigh - Peter MacCallum Cancer Centre Moorabbin Campus (1)
5000 - South Australia - GenesisCare St Andrews Hospital (1)
2139 - Concord - Concord Repatriation General Hospital (1)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (1)
3004 - Melbourne, Southbank - Alfred Health (1)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (1)
5042 - Bedford Park - Flinders Medical Centre (1)
3002 - Melbourne - Peter MacCallum Cancer Centre, East Melbourne campus (1)
Cancer Type
Cancer
Solid tumour
Breast cancer
Gastrointestinal cancer
Breast adenocarcinoma
HER2-positive breast cancer
Thoracic cancer
Gastric cancer
Gastric carcinoma
Gastroesophageal cancer
Gastroesophageal junction adenocarcinoma
Oesophageal cancer
Upper gastrointestinal cancer
Cervical cancer
Colorectal adenocarcinoma
Colorectal cancer
Gynaecological cancer
HPV-related cancer
HPV16-positive cancer
Lower gastrointestinal cancer
Urogenital cancer
Urothelial carcinoma
Viral-related cancer
HER2-negative breast cancer
Lung cancer
Non-small cell lung cancer
Respiratory tract cancer
Endometrial cancer
RAS-mutant colorectal cancer
HER2-low breast cancer
Triple-negative breast cancer
ER-positive breast cancer
HR-positive breast cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy